Rallybio Corporation (RLYB) Stock Price & Analysis
Rallybio Corporation (RLYB) — MoonshotScore 82/100 (Exceptional band), calculated Nov 18, 2026. Price $15.47 (-0.32%), as of the Nov 20, 2026 trading session; market cap $86.6M.
Educational signal · not a buy or sell recommendation · How to read this
Rallybio Corporation · RLYB · NASDAQ
Rallybio Corporation is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Rallybio (RLYB)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet and elite growth, at a cheap price, though quality is only middling; the market is already moving on it. Business Quality: Average; Financial Safety: Fortress; Valuation: Cheap; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 1 of the last 4 reports
- Altman Z 13.32 · Piotroski F 6
- ROE 34.5% · ROA -16.8% · current ratio 28.87
Helping: balance-sheet strength, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 83 | Exceptional | |
| 83 | Exceptional | |
| 83 | Exceptional | |
| 82 | Exceptional | |
| 82 | Exceptional | |
| 82 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $15.47 | |
| Change on the day | -0.32% | |
| Market capitalisation | $86.6M | — |
| Price / earnings (trailing) | 3.32 | |
| Shares traded on the day | 50.5K |
Price & events
Other perspectives
Council score for Rallybio (RLYB): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Rallybio (RLYB), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Rallybio Corporation (RLYB) is listed on NASDAQ. It employs 6 people. The market values it at $86.6M.
What do the latest results show for Rallybio (RLYB)?
Short answer · as of
Against analyst estimates the company has EPS beat 1 of the last 4 reports.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $212,000 | $16M | $2.84 (diluted) |
| Q4 FY2025 | $222,000 | -$6M | — |
| Q1 FY2026 | $212,000 | -$8M | -$1.46 (diluted) |
What are the financial strengths and risks for Rallybio (RLYB)?
Short answer
The MoonshotScore pillars rate balance-sheet strength, an attractive price, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 13.32 · Piotroski F 6. Trailing ratios: ROE 34.5% · ROA -16.8% · current ratio 28.87.
How does Rallybio compare with its peers?
Short answer
Rallybio's score ranks tied for 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| Rallybio (RLYB) — this page | $15.47 | $86.6M | 82 |
| $10.92 Nov 20, 2026 | $99.3M | 82 5-pillar Nov 18, 2026 | |
| $143.82 Nov 20, 2026 | $19.3B | 72 5-pillar Nov 18, 2026 | |
| $3.69 Nov 19, 2026 | $160M | 72 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 63 5-pillar Nov 18, 2026 | |
| $10.02 Nov 20, 2026 | $148M | 61 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 4, 2026
- Transactions
- 52
- Identified insiders
- 10
- Purchases
- 0
- Sales
- 1
- Other transactions
- 51
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held RLYB in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Viking Global | Andreas Halvorsen | Q3 2026 | 0.03% | $9.02M | Held, unchanged |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Rallybio (RLYB)?
- Avenzo Therapeutics Announces Closing of Merger with Rallybio Corporation and Previously Announced $215 Million Concurrent Private Placement
- Rallybio Announces One-for-Two Reverse Stock Split
- Correction to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with Avenzo
Rallybio Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the RLYB research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for RLYB?
RLYB carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is RLYB a good stock to buy?
Stock Expert AI does not rate RLYB buy, sell or hold. Rallybio Corporation carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RLYB stock price today?
The last price recorded for Rallybio Corporation (RLYB), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for RLYB?
Rallybio faces several key risks, including the potential failure to obtain regulatory approval for its product candidates, unfavorable clinical trial results, competition from larger pharmaceutical companies, dependence on strategic alliances, and changes in the regulatory landscape. The company's limited financial resources also pose a risk, as it may need to raise additional capital to fund its operations.
What are the key factors to evaluate for RLYB?
Rallybio Corporation (RLYB) holds a MoonshotScore in the high range. To weigh it, start with the trailing P/E under Price & valuation on this page. Rallybio is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. Not financial advice.
How frequently does RLYB data refresh on this page?
RLYB's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RLYB's recent stock price performance?
Rallybio Corporation (RLYB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on rare diseases with unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RLYB overvalued or undervalued right now?
The trailing P/E of Rallybio Corporation (RLYB) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of RLYB?
Fractional-share availability for Rallybio Corporation (RLYB) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 8 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com